Child Health and the Pediatric Hematology-Oncology Workforce: 2020-2040

Heidi Russell1, Jeffrey Hord2, Colin J Orr3,4

  • 1University of Texas Health Houston School of Public Health, Department of Management, Policy and Community Health, Houston, Texas.

Pediatrics
|February 1, 2024
PubMed

Insights

The number of pediatric hematology-oncology (PHO) specialists is projected to grow 66% by 2040, but significant geographic disparities are expected. This highlights the need for strategic workforce planning to ensure equitable access to care for children with cancer and blood disorders.

Area of Science:

  • Pediatric Subspecialty Workforce Analysis
  • Healthcare Workforce Planning
  • Pediatric Oncology and Hematology

Background:

  • Pediatric hematology-oncology (PHO) is a well-established subspecialty caring for young patients with complex cancers and blood disorders.
  • The current supply of clinically active PHO subspecialists in the U.S. is not well-defined, with some suggesting potential geographic oversaturation.
  • Understanding future workforce needs is critical for ensuring adequate patient access to specialized pediatric care.

Purpose of the Study:

  • To project the future supply of pediatric hematology-oncology subspecialists in the United States through 2040.
  • To identify potential geographic maldistribution patterns within the PHO workforce.
  • To inform strategies for optimizing the PHO subspecialty workforce for improved patient outcomes.

Main Methods:

  • Utilized a microsimulation model to forecast the PHO workforce supply.
  • Incorporated data from the American Board of Pediatrics and existing literature.
  • Analyzed workforce projections under various scenarios, including changes in clinical time and fellowship sizes.

Main Results:

  • The model predicts a 66% growth in the PHO subspecialist workforce by 2040 under baseline assumptions.
  • Alternative scenarios indicated a potential growth variation of ±18% from the baseline.
  • Significant geographic maldistribution is forecasted, with a projected 2.9-fold higher workforce equivalent per child in New England compared to the Mountain division by 2040.

Conclusions:

  • The PHO subspecialty workforce is projected to grow substantially by 2040.
  • Anticipated geographic maldistribution necessitates proactive interventions to ensure equitable care access.
  • Educational, practice, policy, and research initiatives are recommended to address workforce challenges and enhance patient care.

Related Concept Videos

Hematopoiesis01:21

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.3K
Overview of Hematopoiesis01:20

Overview of Hematopoiesis

Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
4.0K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
331
Factors Affecting Erythropoiesis01:24

Factors Affecting Erythropoiesis

The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
3.3K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
1.4K